一分钟看懂
这是一项关于宫颈癌的II 期研究，登记的药物或干预包括Adebrelimab；Paclitaxel；Cisplatin；Carboplatin (AUC 5)，当前状态为尚未开始招募。登记地点显示中国合肥有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Adebrelimab；Paclitaxel；Cisplatin；Carboplatin (AUC 5) · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui province hospital · 合肥
公开的入选条件
- * Aged 18 to 75 years.
- * Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix; FIGO 2018 stage IB3 or IIA2, or carefully selected stage IIB or IIIC1r disease following multidisciplinary team evaluation, with a maximum primary tum
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- * Able to provide adequate tumor tissue for biomarker testing, defined as at least 18 qualified tissue sections.
- * No prior surgery for cervical cancer, except staging procedures, and no prior radiotherapy, chemotherapy, systemic anticancer therapy, investigational therapy, or immunotherapy for cervical cancer.
- * At least one measurable lesion according to RECIST version 1.1, defined as a tumor lesion with a longest diameter ≥10 mm on CT or a lymph node with a short-axis diameter ≥15 mm on CT.
- * Estimated life expectancy ≥6 months.
- * No primary or metastatic central nervous system disease.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07811375；登记信息更新于 2026-09-10。